A phases II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

被引：0
|
作者：
Chan, John K.
Deng, Wei
Higgins, Robert
Bonebrake, Albert J.
Hicks, Michael
Tewari, Krishnansu Sujata
Gaillard, Stephanie
Ramirez, Pedro T.
Monk, Bradley J.
机构：
[1] Calif Pacific Palo Alto Med Fdn, Sutter Res Inst, San Francisco, CA USA
[2] Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Canc Res Ozarks Cox Hlth, Springfield, MO USA
[5] Michigan Canc Res Consortium, Pontiac, MI USA
[6] UC Irvine Med Ctr, Orange, CA USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Univ Arizona, Ctr Canc, Phoenix, AZ USA
[10] Creighton Univ, Sch Med, Dign Hlth St Josephs Hosp, Phoenix, AZ USA
[11] Creighton Univ, Med Ctr, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16599
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16599
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
    Chan, John K.
    Deng, Wei
    Higgins, Robert V.
    Tewari, Krishnansu S.
    Bonebrake, Albert J.
    Hicks, Michael
    Gaillard, Stephanie
    Ramirez, Pedro T.
    Chafe, Weldon
    Monk, Bradley J.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2017, 146 (03) : 554 - 559
  • [2] A phase II trial of brivanib in recurrent or persistent enclometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Powell, Matthew A.
    Sill, Michael W.
    Goodfellow, Paul J.
    Benbrook, Doris M.
    Lankes, Heather A.
    Leslie, Kimberly K.
    Jeske, Yvette
    Mannel, Robert S.
    Spillman, Monique A.
    Lee, Paula S.
    Hoffman, James S.
    McMeekin, D. Scott
    Pollock, Pamela M.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 38 - 43
  • [3] A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study.
    McCourt, Carolyn K.
    Powell, Matthew
    Tenney, Meaghan Elizabeth
    Kushner, David M.
    Rotmensch, Jacob
    Kendrick, James Erasmus
    Warshal, David Philip
    Deng, Wei
    Saltzman, Joel N.
    Dizon, Don S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study
    McCourt, Carolyn K.
    Deng, Wei
    Dizon, Don S.
    Lankes, Heather. A.
    Birrer, Michael J.
    Lomme, Michele M.
    Powell, Matthew A.
    Kendrick, James E.
    Saltzman, Joel N.
    Warshal, David
    Tenney, Meaghan E.
    Kushner, David M.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 101 - 106
  • [5] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Bender, David
    Sill, Michael W.
    Lankes, Heather A.
    Reyes, Henry D.
    Darus, Christopher J.
    Delmore, James E.
    Rotmensch, Jacob
    Gray, Heidi J.
    Mannel, Robert S.
    Schilder, Jeanne M.
    Hunter, Mark I.
    McCourt, Carolyn K.
    Samuelson, Megan I.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
  • [6] Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Burger, Robert A.
    Deng, Wei
    Makker, Vicky
    Collins, Yvonne
    Gray, Heidi
    Debernardo, Robert
    Martin, Lainie P.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 466 - 470
  • [7] Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study
    Muggia, FM
    Blessing, JA
    Waggoner, S
    Berek, JS
    Monk, BJ
    Sorosky, J
    Pearl, ML
    GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 108 - 111
  • [8] A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study
    Kunos, Charles
    Deng, Wei
    Dawson, Dawn
    Lea, Jayanthi S.
    Zanotti, Kristine M.
    Gray, Heidi J.
    Bender, David P.
    Guaglianone, Perry P.
    Carter, Jori S.
    Moore, Kathleen N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (03) : 484 - 492
  • [9] Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Bigler, LR
    Thigpen, JT
    Blessing, JA
    Fiorica, J
    Monk, BJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (05) : 871 - 874
  • [10] A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
    Chan, John K.
    Brady, William
    Monk, Bradley J.
    Brown, Jubilee
    Shahin, Mark S.
    Rose, Peter G.
    Kim, Jae-Hoon
    Secord, Angeles Alvarez
    Walker, Joan L.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 247 - 252
12345